Literature DB >> 14985923

The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.

Judith A Siuciak1, Remie A Fujiwara.   

Abstract

RATIONALE: Recent studies have reported antidepressant-like activities of the dopamine D2/D3 agonist pramipexole in the chronic mild stress model and in the forced swim test, suggesting that D3 receptor agonists may represent a new class of antidepressant drugs. However, the relative contribution of D2 or D3 receptors to the activity of pramipexole in these models is unclear.
OBJECTIVES: The aim of the current studies was to explore the role of dopamine D2 and D3 receptors in the activity of pramipexole in the mouse forced swim test.
METHODS: The effect of pramipexole (0.1-3.2 mg/kg) in the mouse forced swim test was examined both in conjunction with D2 and D3 receptor antagonists (haloperidol (0.1-1 mg/kg) and LU-201640 (A-437203, 5.6-17.8 mg/kg), as well as in D3 receptor knockout mice obtained on two different background strains (C57BL/6J and B6129SF2/J). Locomotor activity was also assessed following pramipexole administration. RESULTS. Pramipexole produced dose-dependent reductions in immobility in the forced swim test at doses that did not produce generalized increases in locomotor activity. LU-201640, the D3 selective antagonist, failed to block the antidepressant-like effects of pramipexole. In contrast, the efficacy of pramipexole in the forced swim test was completely blocked by the D2 antagonist, haloperidol. No baseline differences were observed between knockout and wild-type mice from either background strain in locomotor activity or in the forced swim test. Furthermore, in both background strains, pramipexole showed similar efficacy in the forced swim test for both wild-type and knockout mice.
CONCLUSIONS: Taken together, these studies suggest that the D2 receptor rather than the D3 receptor is important for the antidepressant-like activity observed for pramipexole in the mouse forced swim test.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985923     DOI: 10.1007/s00213-004-1809-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

Review 1.  Dopamine receptors--physiological understanding to therapeutic intervention potential.

Authors:  G Emilien; J M Maloteaux; M Geurts; K Hoogenberg; S Cragg
Journal:  Pharmacol Ther       Date:  1999-11       Impact factor: 12.310

2.  The effects of antidepressants and electroconvulsive shocks on the functioning of the mesolimbic dopaminergic system: a behavioral study.

Authors:  A Plaznik; W Kostowski
Journal:  Eur J Pharmacol       Date:  1987-03-31       Impact factor: 4.432

3.  Evidence of dopamine involvement in the effect of repeated treatment with various antidepressants in the behavioural 'despair' test in rats.

Authors:  F Borsini; L Pulvirenti; R Samanin
Journal:  Eur J Pharmacol       Date:  1985-04-02       Impact factor: 4.432

Review 4.  Neurobiology of depression: focus on dopamine.

Authors:  H C Fibiger
Journal:  Adv Biochem Psychopharmacol       Date:  1995

5.  Synergistic effect of pramipexole and sertraline in the forced swimming test.

Authors:  J Maj; Z Rogóz
Journal:  Pol J Pharmacol       Date:  1999 Nov-Dec

6.  Antidepressant-like effects of dopamine agonists in an animal model of depression.

Authors:  R Muscat; M Papp; P Willner
Journal:  Biol Psychiatry       Date:  1992-05-01       Impact factor: 13.382

Review 7.  Dopamine and depression: a review of recent evidence. I. Empirical studies.

Authors:  P Willner
Journal:  Brain Res       Date:  1983-12       Impact factor: 3.252

8.  Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain.

Authors:  J Maj; M Dziedzicka-Wasylewska; R Rogoz; Z Rogóz
Journal:  Eur J Pharmacol       Date:  1998-06-12       Impact factor: 4.432

Review 9.  Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments.

Authors:  P Willner
Journal:  Brain Res       Date:  1983-12       Impact factor: 3.252

10.  A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression.

Authors:  C Theohar; K Fischer-Cornelssen; H Brosch; E K Fischer; D Petrovic
Journal:  Arzneimittelforschung       Date:  1982
View more
  12 in total

Review 1.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

2.  The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice.

Authors:  Wei-Li Chang; Mark A Geyer; Mahalah R Buell; Martin Weber; Neal R Swerdlow
Journal:  Behav Pharmacol       Date:  2010-03       Impact factor: 2.293

Review 3.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

4.  Insulin regulates astrocyte gliotransmission and modulates behavior.

Authors:  Weikang Cai; Chang Xue; Masaji Sakaguchi; Masahiro Konishi; Alireza Shirazian; Heather A Ferris; Mengyao E Li; Ruichao Yu; Andre Kleinridders; Emmanuel N Pothos; C Ronald Kahn
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808

5.  Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats.

Authors:  Kouhei Kitagawa; Yoshihisa Kitamura; Toshiaki Miyazaki; Junya Miyaoka; Hiromu Kawasaki; Masato Asanuma; Toshiaki Sendo; Yutaka Gomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-03-10       Impact factor: 3.000

6.  Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions.

Authors:  Maria T G Perona; Shonna Waters; Frank Scott Hall; Ichiro Sora; Klaus-Peter Lesch; Dennis L Murphy; Marc Caron; George R Uhl
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

7.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Authors:  Judith A Siuciak; Sheryl A McCarthy; Douglas S Chapin; Ashley N Martin
Journal:  Psychopharmacology (Berl)       Date:  2007-12-01       Impact factor: 4.530

8.  Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits.

Authors:  Judith A Siuciak; Sheryl A McCarthy; A N Martin; D S Chapin; J Stock; D M Nadeau; S Kantesaria; D Bryce-Pritt; S McLean
Journal:  Psychopharmacology (Berl)       Date:  2007-06-10       Impact factor: 4.415

9.  Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.

Authors:  S Carnicella; G Drui; S Boulet; C Carcenac; M Favier; T Duran; M Savasta
Journal:  Transl Psychiatry       Date:  2014-06-17       Impact factor: 6.222

10.  Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease.

Authors:  Satoka Kasai; Toru Yoshihara; Olga Lopatina; Katsuhiko Ishihara; Haruhiro Higashida
Journal:  Front Behav Neurosci       Date:  2017-05-03       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.